Augmented Reality Rehabilitation for Acquired Brain Injury

N/A

Recruiting

Research Sponsored by University of Alberta

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 12 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial seeks to use AR to make rehab therapies more engaging & fun for ABI patients, improving adherence & clinical outcomes.

Who is the study for?

This trial is for adults at the Glenrose Rehabilitation Hospital in Edmonton, Canada with mild to moderate acquired brain injury. Participants must speak English and have enough upper-limb strength and coordination to use an AR headset. It's not for children, those with severe brain injuries or cognitive disorders, severe aphasia, communication disorders that affect understanding verbal commands, previous neurological/psychiatric conditions, substance misuse issues, or impairments limiting interaction with AR.

What is being tested?

The study tests augmented reality (AR) therapies called GlenXRose for acquired brain injury rehabilitation. The goal is to see if gamifying therapy through AR can make it more engaging and improve patient adherence compared to traditional methods. This will be assessed alongside routine care while considering clinician feedback and financial costs.

What are the potential side effects?

While specific side effects are not detailed in this summary, potential side effects may include discomfort from using the AR headset or fatigue due to increased engagement during rehabilitation sessions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Adherence - Attendance

Adherence - Clinician Reported

Adherence - Self Reported

+3 more

Secondary study objectives

Cognitive Functioning - Behaviour

Cognitive Functioning - LOTCA

Cognitive Functioning - SCATBI

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Augmented Reality Delivered Therapy + Standard Clinical CareExperimental Treatment1 Intervention

The GlenXRose augmented reality therapies will be delivered to participants using a head-mounted device to allow acquired brain injury rehabilitation therapy and practice. Participants will also receive routine clinical care provided by clinicians.

Group II: Standard Clinical CareActive Control1 Intervention

Participants will receive routine clinical care provided by clinicians.

Do I qualify?Apply below to find out